Paxalisib for focal cortical dysplasia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Dec 2025: Trial registered, NCT07287202
  2. 14 Jul 2026: Trial started, NCT07287202

The trials

NCT07287202: Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

State
Under way
Phase
Phase 1 and Phase 2
People
12 planned
Started
14 Jul 2026
Primary completion
Feb 2027
Arms
Arm1, Arm2
Results
None posted
  1. 17 Dec 2025: Trial registered
  2. 14 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as SVG103.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.